Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Introduced at SABCS

MELBOURNE, Australia, Nov. 30, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) immediately advises that the finished Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imaging candidate, TLX250-CDx (⁸⁹Zr-DFO-girentuximab), in sufferers with triple-negative breast most cancers (TNBC), might be introduced on the 2023 San Antonio Breast Cancer Symposium® (SABCS) taking place from December 5-9, 2023.

Dr. Caroline Rousseau, Principal Investigator for the OPALESCENCE examine (ClinicalTrials.gov ID NCT04758780) on the Institut de Cancérologie de l’Ouest (ICO) in St Herblain (France), will ship top-line outcomes as a poster presentation at 5pm CT on Wednesday December 6.

The major goal of the OPALESCENCE examine was to guage how CAIX-targeted imaging with PET will be utilised for the analysis and staging of TNBC and to develop a deeper understanding of CAIX as a possible therapeutic goal on this affected person inhabitants with a big unmet medical want.

SABCS is the most important and most prestigious scientific gathering on breast most cancers analysis worldwide. Visit http://www.sabcs.org/ for extra data on the congress.

About the Institut de Cancérologie de l’Ouest (ICO)

ICO is a 1,400 skilled sturdy not-for-profit heart combating in opposition to most cancers. It welcomes near 48,000 sufferers per yr, and conducts the mission and repair of a public hospital. Strengthened by its 4 missions – Prevention, Care, Research and Teaching – ICO provides broad, state-of-the-art experience that’s solely devoted to cancerology.

Advanced medication on the service of sufferers: specialising in oncology, ICO professionals present sufferers with personalised, modern and multidisciplinary care at each stage of their therapy. From speedy analysis to surgical procedure, chemotherapy and radiotherapy, care additionally extends to supportive care, which is very developed at ICO.

Story continues

The integration of care, analysis and innovation is integral to ICO. Research actions, that are a selected mission at ICO, are undertaken from idea all over to medical trials. Research is performed in all disciplines of cancerology: medical oncology, radiotherapy, surgical procedure, anaesthesia, nuclear medication, medical imagery, help care, and human sciences. Patients who’re cared for at ICO obtain privileged access to leading edge medical trials in cancerology. The mission of the Innovation Unit is to help innovation in oncology by aiding each inner and exterior venture leaders from the preliminary thought to the operational implementation of the innovation. Through its instructing mission and educational experience, ICO contributes to the coaching of tomorrow’s most cancers professionals. For extra data contact: [email protected]

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical firm centered on the event and commercialisation of diagnostic and therapeutic radiopharmaceuticals and related medical gadgets. Telix is headquartered in Melbourne, Australia with worldwide operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is creating a portfolio of clinical-stage merchandise that goals to handle vital unmet medical wants in oncology and uncommon ailments. Telix is listed on the Australian Securities Exchange (ASX: TLX).

Visit www.telixpharma.com for additional details about Telix, together with particulars of the latest share value, bulletins made to the ASX, investor and analyst shows, information releases, occasion particulars and different publications that could be of curiosity. You may also observe Telix on LinkedIn.

TLX250-CDx has not obtained a advertising authorisation in any jurisdiction. Telix’s lead imaging product, gallium-68 (⁶⁸Ga) gozetotide injection (also referred to as ⁶⁸Ga PSMA-11 and marketed beneath the model title Illuccix®), has been accepted by the U.S. Food and Drug Administration (FDA),^[1] by the Australian Therapeutic Goods Administration (TGA),^[2] and by Health Canada.^[3]

Telix’s SENSEI® ultra-miniaturised robotic gamma probe is registered as a Class 1 gadget with the FDA, and has attained a Conformité Européenne (CE) Mark to be used within the European Economic Area for intra-operative detection of sentinel lymph nodes.^[4]

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: [email protected]

Legal Notices

This announcement isn’t supposed as promotion or promoting directed to any healthcare skilled or different viewers in any nation worldwide (together with Australia, United States and the United Kingdom). This announcement might embrace forward-looking statements that relate to anticipated future occasions, monetary efficiency, plans, methods or business developments.  Forward-looking statements can typically be recognized by way of phrases resembling “might”, “anticipate”, “intend”, “plan”, “estimate”, “anticipate”, “outlook”, “forecast” and “steerage”, or different comparable phrases. Forward-looking statements contain identified and unknown dangers, uncertainties and different elements that will trigger our precise outcomes, ranges of exercise, efficiency or achievements to vary materially from any future outcomes, ranges of exercise, efficiency or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based mostly on the Company’s good-faith assumptions as to the monetary, market, regulatory and different dangers and concerns that exist and have an effect on the Company’s business and operations sooner or later and there will be no assurance that any of the assumptions will show to be right. In the context of Telix’s business, forward-looking statements might embrace, however will not be restricted to, statements about: the initiation, timing, progress and outcomes of Telix’s preclinical and medical research, and Telix’s analysis and growth packages; Telix’s capability to advance product candidates into, enrol and efficiently full, medical research, together with multi-national medical trials; the timing or probability of regulatory filings and approvals, manufacturing actions and product advertising actions; the commercialisation of Telix’s product candidates, if or once they have been accepted; estimates of Telix’s bills, future revenues and capital necessities; Telix’s monetary efficiency; developments referring to Telix’s opponents and trade; and the pricing and reimbursement of Telix’s product candidates, if and after they’ve been accepted. Telix’s precise outcomes, efficiency or achievements could also be materially totally different from these which can be expressed or implied by such statements, and the variations could also be hostile. Accordingly, you shouldn’t place undue reliance on these forward-looking statements.

Except as required by relevant legal guidelines or laws, Telix doesn’t undertake to publicly update or overview any forward-looking statements. Past efficiency can’t be relied on as a information to future efficiency. Readers ought to learn this announcement along with our materials dangers, as disclosed in our most lately filed studies with the ASX and on our web site.

©2023 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals and Illuccix title and brand are emblems of Telix Pharmaceuticals Limited and its associates (all rights reserved).

View unique content material to obtain multimedia:https://www.prnewswire.com/apac/news-releases/phase-ii-opalescence-study-of-tlx250-cdx-in-triple-negative-breast-cancer-to-be-presented-at-sabcs-302001181.html

SOURCE Telix Pharmaceuticals Limited